COLUMBIA, Md.--(BUSINESS WIRE)--Hemagen Diagnostics, Inc. (OTC:HMGN.OB) a biotechnology Company that develops, manufactures and markets proprietary medical diagnostic test kits, today reported its operating results for the fiscal year ended September 30, 2006. The net income for the year ended September 30, 2006 was $313,000 or $0.02 per share, which included a gain on sale of a building of $865,000, compared to a net loss of ($1,337,000) or ($0.09) per share during the prior fiscal year.
